APO Research
Talk to an analyst

APO RESEARCH · REPORT

Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

20 December 2025195 pages

Choose your research edition.

Industry ResearchDiphtheria, Tetanus, and Pertussis (DTaP) Vaccine Industry Research Report 2026122 pages · $2,950 USDIndustry Growth & TrendsGlobal Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Industry Growth and Trends Forecast to 2032102 pages · $3,450 USDMarket StructureGlobal Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine include Astellas Pharma US, Emergent BioSolutions Inc, Merck Sharp & Dohme Corp, Protein Sciences Corporation, Sanofi Pasteur, Seqirus, AstraZeneca, GlaxoSmithKline and Pfizer Inc, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine market size, projected growth trends, production technologies, key applications, and end-use industries.

Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Segment by Company

Astellas Pharma US

Emergent BioSolutions Inc

Merck Sharp & Dohme Corp

Protein Sciences Corporation

Sanofi Pasteur

Seqirus

AstraZeneca

GlaxoSmithKline

Pfizer Inc

Lanzhou Institute of Biological Products Co., Ltd

Novartis AG

Johnson & Johnson

Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Segment by Type

Immune DTaP Vaccine

Therapy DTaP Vaccine

Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Segment by Application

Adult

Pediatric

Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Industry Trends Table 2. Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Industry Drivers Table 3. Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Industry Opportunities and Challenges Table 4. Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Industry Restraints Table 5. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Manufacturers (W Units) & (2021-2026) Table 8. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Manufacturers Table 9. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Manufacturers, Product Type & Application Table 13. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Immune DTaP Vaccine Table 17. Major Manufacturers of Therapy DTaP Vaccine Table 18. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Type 2021 VS 2025 VS 2032 (W Units) Table 19. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Type (2021-2026) & (W Units) Table 20. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Type (2027-2032) & (W Units) Table 21. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Type (2021-2026) Table 22. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Type (2027-2032) Table 23. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Type 2021 VS 2025 VS 2032 (W Units) Table 24. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Type (2021-2026) & (W Units) Table 25. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Type (2027-2032) & (W Units) Table 26. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Type (2021-2026) Table 27. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Type (2027-2032) Table 28. Major Manufacturers of Adult Table 29. Major Manufacturers of Pediatric Table 30. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Application 2021 VS 2025 VS 2032 (W Units) Table 31. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Application (2021-2026) & (W Units) Table 32. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Application (2027-2032) & (W Units) Table 33. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Application (2021-2026) Table 34. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Application (2027-2032) Table 35. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Application 2021 VS 2025 VS 2032 (W Units) Table 36. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Application (2021-2026) & (W Units) Table 37. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Application (2027-2032) & (W Units) Table 38. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Application (2021-2026) Table 39. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Application (2027-2032) Table 40. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Region: 2021 VS 2025 VS 2032 (W Units) Table 41. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Region (2021-2026) & (W Units) Table 42. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Region (2021-2026) Table 43. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Forecasted by Region (2027-2032) & (W Units) Table 44. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Forecasted Market Share by Region (2027-2032) Table 45. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (W Units) Table 46. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Country (2021-2026) & (W Units) Table 47. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Country (2027-2032) & (W Units) Table 48. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (W Units) Table 49. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Country (2021-2026) & (W Units) Table 50. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Country (2027-2032) & (W Units) Table 51. Asia Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (W Units) Table 52. Asia Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Country (2021-2026) & (W Units) Table 53. Asia Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Country (2027-2032) & (W Units) Table 54. South America, Middle East and Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (W Units) Table 55. South America, Middle East and Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Country (2021-2026) & (W Units) Table 56. South America, Middle East and Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Country (2027-2032) & (W Units) Table 57. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 58. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Region (2021-2026) & (US$ Million) Table 59. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Region (2027-2032) & (US$ Million) Table 60. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Region (2021-2026) Table 61. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Region (2027-2032) Table 62. Astellas Pharma US Company Information Table 63. Astellas Pharma US Business Overview Table 64. Astellas Pharma US Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 65. Astellas Pharma US Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Portfolio Table 66. Astellas Pharma US Recent Development Table 67. Emergent BioSolutions Inc Company Information Table 68. Emergent BioSolutions Inc Business Overview Table 69. Emergent BioSolutions Inc Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 70. Emergent BioSolutions Inc Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Portfolio Table 71. Emergent BioSolutions Inc Recent Development Table 72. Merck Sharp & Dohme Corp Company Information Table 73. Merck Sharp & Dohme Corp Business Overview Table 74. Merck Sharp & Dohme Corp Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 75. Merck Sharp & Dohme Corp Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Portfolio Table 76. Merck Sharp & Dohme Corp Recent Development Table 77. Protein Sciences Corporation Company Information Table 78. Protein Sciences Corporation Business Overview Table 79. Protein Sciences Corporation Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 80. Protein Sciences Corporation Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Portfolio Table 81. Protein Sciences Corporation Recent Development Table 82. Sanofi Pasteur Company Information Table 83. Sanofi Pasteur Business Overview Table 84. Sanofi Pasteur Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 85. Sanofi Pasteur Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Portfolio Table 86. Sanofi Pasteur Recent Development Table 87. Seqirus Company Information Table 88. Seqirus Business Overview Table 89. Seqirus Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 90. Seqirus Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Portfolio Table 91. Seqirus Recent Development Table 92. AstraZeneca Company Information Table 93. AstraZeneca Business Overview Table 94. AstraZeneca Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 95. AstraZeneca Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Portfolio Table 96. AstraZeneca Recent Development Table 97. GlaxoSmithKline Company Information Table 98. GlaxoSmithKline Business Overview Table 99. GlaxoSmithKline Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 100. GlaxoSmithKline Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Portfolio Table 101. GlaxoSmithKline Recent Development Table 102. Pfizer Inc Company Information Table 103. Pfizer Inc Business Overview Table 104. Pfizer Inc Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 105. Pfizer Inc Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Portfolio Table 106. Pfizer Inc Recent Development Table 107. Lanzhou Institute of Biological Products Co., Ltd Company Information Table 108. Lanzhou Institute of Biological Products Co., Ltd Business Overview Table 109. Lanzhou Institute of Biological Products Co., Ltd Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 110. Lanzhou Institute of Biological Products Co., Ltd Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Portfolio Table 111. Lanzhou Institute of Biological Products Co., Ltd Recent Development Table 112. Novartis AG Company Information Table 113. Novartis AG Business Overview Table 114. Novartis AG Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 115. Novartis AG Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Portfolio Table 116. Novartis AG Recent Development Table 117. Johnson & Johnson Company Information Table 118. Johnson & Johnson Business Overview Table 119. Johnson & Johnson Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 120. Johnson & Johnson Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Portfolio Table 121. Johnson & Johnson Recent Development Table 122. Key Raw Materials Table 123. Raw Materials Key Suppliers Table 124. Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Distributors List Table 125. Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Customers List Table 126. Research Programs/Design for This Report Table 127. Authors List of This Report Table 128. Secondary Sources Table 129. Primary Sources List of Figures Figure 1. Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Image Figure 2. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size (2021-2032) & (US$ Million) Figure 4. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (2021-2032) & (W Units) Figure 5. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Immune DTaP Vaccine Image Figure 9. Therapy DTaP Vaccine Image Figure 10. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Type (2021 VS 2025 VS 2032) & (W Units) Figure 11. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share 2021 VS 2025 VS 2032 Figure 12. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Type (2021-2032) Figure 13. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Type (2021 VS 2025 VS 2032) & (W Units) Figure 14. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share 2021 VS 2025 VS 2032 Figure 15. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Type (2021-2032) Figure 16. Adult Image Figure 17. Pediatric Image Figure 18. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Application (2021 VS 2025 VS 2032) & (W Units) Figure 19. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share 2021 VS 2025 VS 2032 Figure 20. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Application (2021-2032) Figure 21. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Application (2021 VS 2025 VS 2032) & (W Units) Figure 22. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share 2021 VS 2025 VS 2032 Figure 23. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Application (2021-2032) Figure 24. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales and Growth Rate (2021-2032) & (W Units) Figure 25. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Country (2021-2032) Figure 26. U.S. Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales and Growth Rate (2021-2032) & (W Units) Figure 27. Canada Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales and Growth Rate (2021-2032) & (W Units) Figure 28. Mexico Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales and Growth Rate (2021-2032) & (W Units) Figure 29. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales and Growth Rate (2021-2032) & (W Units) Figure 30. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Country (2021-2032) Figure 31. Germany Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales and Growth Rate (2021-2032) & (W Units) Figure 32. France Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales and Growth Rate (2021-2032) & (W Units) Figure 33. U.K. Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales and Growth Rate (2021-2032) & (W Units) Figure 34. Italy Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales and Growth Rate (2021-2032) & (W Units) Figure 35. Netherlands Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales and Growth Rate (2021-2032) & (W Units) Figure 36. Asia Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales and Growth Rate (2021-2032) & (W Units) Figure 37. Asia Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Country (2021-2032) Figure 38. China Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales and Growth Rate (2021-2032) & (W Units) Figure 39. Japan Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales and Growth Rate (2021-2032) & (W Units) Figure 40. South Korea Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales and Growth Rate (2021-2032) & (W Units) Figure 41. Southeast Asia Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales and Growth Rate (2021-2032) & (W Units) Figure 42. India Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales and Growth Rate (2021-2032) & (W Units) Figure 43. Australia Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales and Growth Rate (2021-2032) & (W Units) Figure 44. South America, Middle East and Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales and Growth Rate (2021-2032) & (W Units) Figure 45. South America, Middle East and Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Country (2021-2032) Figure 46. Brazil Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales and Growth Rate (2021-2032) & (W Units) Figure 47. South Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales and Growth Rate (2021-2032) & (W Units) Figure 48. Saudi Arabia Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales and Growth Rate (2021-2032) & (W Units) Figure 49. Turkey Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales and Growth Rate (2021-2032) & (W Units) Figure 50. Argentina Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales and Growth Rate (2021-2032) & (W Units) Figure 51. UAE Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales and Growth Rate (2021-2032) & (W Units) Figure 52. Egypt Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales and Growth Rate (2021-2032) & (W Units) Figure 53. Chile Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales and Growth Rate (2021-2032) & (W Units) Figure 54. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 55. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 56. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue (2021-2032) & (US$ Million) Figure 57. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 58. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue (2021-2032) & (US$ Million) Figure 59. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 60. Asia-Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue (2021-2032) & (US$ Million) Figure 61. Asia-Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. South America, Middle East and Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue (2021-2032) & (US$ Million) Figure 63. South America, Middle East and Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Value Chain Figure 65. Manufacturing Cost Structure Figure 66. Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Production Mode & Process Figure 67. Direct Comparison with Distribution Share Figure 68. Distributors Profiles Figure 69. Years Considered Figure 70. Research Process Figure 71. Key Executives Interviewed

Scope & coverage.

Types
  • Immune DTaP Vaccine
  • Therapy DTaP Vaccine
Applications
  • Adult
  • Pediatric
Companies covered
  • Astellas Pharma US
  • Emergent BioSolutions Inc
  • Merck Sharp & Dohme Corp
  • Protein Sciences Corporation
  • Sanofi Pasteur
  • Seqirus
  • AstraZeneca
  • GlaxoSmithKline
  • Pfizer Inc
  • Lanzhou Institute of Biological Products Co., Ltd
  • Novartis AG
  • Johnson & Johnson

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Dynamics
  1. 2.1 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Industry Trends
  2. 2.2 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Industry Drivers
  3. 2.3 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Industry Opportunities and Challenges
  4. 2.4 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Industry Restraints
3 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market by Manufacturers
  1. 3.1 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Manufacturers (2021-2026)
  3. 3.3 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Manufacturers, Product Type & Application
  7. 3.7 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Tier 1, Tier 2, and Tier 3
4 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market by Type
  1. 4.1 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Type Introduction
  2. 4.1.1 Immune DTaP Vaccine
  3. 4.1.2 Therapy DTaP Vaccine
  4. 4.2 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Type
  5. 4.2.1 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Type (2021-2032)
  7. 4.2.3 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Type (2021-2032)
  8. 4.3 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Type
  9. 4.3.1 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Type (2021-2032)
  11. 4.3.3 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Type (2021-2032)
5 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market by Application
  1. 5.1 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Application Introduction
  2. 5.1.1 Adult
  3. 5.1.2 Pediatric
  4. 5.2 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Application
  5. 5.2.1 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Application (2021-2032)
  7. 5.2.3 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Application (2021-2032)
  8. 5.3 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Application
  9. 5.3.1 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Application (2021-2032)
  11. 5.3.3 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Application (2021-2032)
6 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Region
  1. 6.1 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Region (2021-2032)
  3. 6.2.1 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Region (2021-2026)
  4. 6.2.2 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Region
  1. 7.1 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Region
  2. 7.1.1 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Region (2021-2026)
  4. 7.1.3 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Region (2027-2032)
  5. 7.1.4 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue (2021-2032)
  8. 7.2.2 North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue (2021-2032)
  11. 7.3.2 Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Astellas Pharma US
  2. 8.1.1 Astellas Pharma US Company Information
  3. 8.1.2 Astellas Pharma US Business Overview
  4. 8.1.3 Astellas Pharma US Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Astellas Pharma US Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Portfolio
  6. 8.1.5 Astellas Pharma US Recent Developments
  7. 8.2 Emergent BioSolutions Inc
  8. 8.2.1 Emergent BioSolutions Inc Company Information
  9. 8.2.2 Emergent BioSolutions Inc Business Overview
  10. 8.2.3 Emergent BioSolutions Inc Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Emergent BioSolutions Inc Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Portfolio
  12. 8.2.5 Emergent BioSolutions Inc Recent Developments
  13. 8.3 Merck Sharp & Dohme Corp
  14. 8.3.1 Merck Sharp & Dohme Corp Company Information
  15. 8.3.2 Merck Sharp & Dohme Corp Business Overview
  16. 8.3.3 Merck Sharp & Dohme Corp Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Merck Sharp & Dohme Corp Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Portfolio
  18. 8.3.5 Merck Sharp & Dohme Corp Recent Developments
  19. 8.4 Protein Sciences Corporation
  20. 8.4.1 Protein Sciences Corporation Company Information
  21. 8.4.2 Protein Sciences Corporation Business Overview
  22. 8.4.3 Protein Sciences Corporation Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Protein Sciences Corporation Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Portfolio
  24. 8.4.5 Protein Sciences Corporation Recent Developments
  25. 8.5 Sanofi Pasteur
  26. 8.5.1 Sanofi Pasteur Company Information
  27. 8.5.2 Sanofi Pasteur Business Overview
  28. 8.5.3 Sanofi Pasteur Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Sanofi Pasteur Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Portfolio
  30. 8.5.5 Sanofi Pasteur Recent Developments
  31. 8.6 Seqirus
  32. 8.6.1 Seqirus Company Information
  33. 8.6.2 Seqirus Business Overview
  34. 8.6.3 Seqirus Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Seqirus Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Portfolio
  36. 8.6.5 Seqirus Recent Developments
  37. 8.7 AstraZeneca
  38. 8.7.1 AstraZeneca Company Information
  39. 8.7.2 AstraZeneca Business Overview
  40. 8.7.3 AstraZeneca Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 AstraZeneca Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Portfolio
  42. 8.7.5 AstraZeneca Recent Developments
  43. 8.8 GlaxoSmithKline
  44. 8.8.1 GlaxoSmithKline Company Information
  45. 8.8.2 GlaxoSmithKline Business Overview
  46. 8.8.3 GlaxoSmithKline Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 GlaxoSmithKline Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Portfolio
  48. 8.8.5 GlaxoSmithKline Recent Developments
  49. 8.9 Pfizer Inc
  50. 8.9.1 Pfizer Inc Company Information
  51. 8.9.2 Pfizer Inc Business Overview
  52. 8.9.3 Pfizer Inc Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Pfizer Inc Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Portfolio
  54. 8.9.5 Pfizer Inc Recent Developments
  55. 8.10 Lanzhou Institute of Biological Products Co., Ltd
  56. 8.10.1 Lanzhou Institute of Biological Products Co., Ltd Company Information
  57. 8.10.2 Lanzhou Institute of Biological Products Co., Ltd Business Overview
  58. 8.10.3 Lanzhou Institute of Biological Products Co., Ltd Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Lanzhou Institute of Biological Products Co., Ltd Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Portfolio
  60. 8.10.5 Lanzhou Institute of Biological Products Co., Ltd Recent Developments
  61. 8.11 Novartis AG
  62. 8.11.1 Novartis AG Company Information
  63. 8.11.2 Novartis AG Business Overview
  64. 8.11.3 Novartis AG Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Novartis AG Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Portfolio
  66. 8.11.5 Novartis AG Recent Developments
  67. 8.12 Johnson & Johnson
  68. 8.12.1 Johnson & Johnson Company Information
  69. 8.12.2 Johnson & Johnson Business Overview
  70. 8.12.3 Johnson & Johnson Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Johnson & Johnson Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Portfolio
  72. 8.12.5 Johnson & Johnson Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Value Chain Analysis
  2. 9.1.1 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Production Mode & Process
  6. 9.2 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Distributors
  9. 9.2.3 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst